{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:52:56Z","timestamp":1774633976729,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T00:00:00Z","timestamp":1365033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T00:00:00Z","timestamp":1365033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/gt.2013.17","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T10:19:04Z","timestamp":1365070744000},"page":"939-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine"],"prefix":"10.1038","volume":"20","author":[{"given":"O","family":"Igoucheva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Grazzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Pidich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D M","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Larijani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Farber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Lorton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Rodeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Alexeev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"BFgt201317_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-008-0568-4","volume":"58","author":"L Engell-Noerregaard","year":"2009","unstructured":"Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM . Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58: 1\u201314.","journal-title":"Cancer Immunol Immunother"},{"key":"BFgt201317_CR2","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CJI.0b013e3181f05b91","volume":"33","author":"SL Goff","year":"2010","unstructured":"Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother 2010; 33: 840\u2013847.","journal-title":"J Immunother"},{"key":"BFgt201317_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535\u2013546.","journal-title":"Blood"},{"key":"BFgt201317_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","volume":"21","author":"SA Rosenberg","year":"2009","unstructured":"Rosenberg SA, Dudley ME . Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21: 233\u2013240.","journal-title":"Curr Opin Immunol"},{"key":"BFgt201317_CR5","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2165\/11594010-000000000-00000","volume":"71","author":"F Cameron","year":"2011","unstructured":"Cameron F, Whiteside G, Perry C . Ipilimumab: first global approval. Drugs 2011; 71: 1093\u20131104.","journal-title":"Drugs"},{"key":"BFgt201317_CR6","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1755-148X.2010.00737.x","volume":"23","author":"TF Gajewski","year":"2010","unstructured":"Gajewski TF . Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell Melanoma Res 2010; 23: 580\u2013581.","journal-title":"Pigment Cell Melanoma Res"},{"key":"BFgt201317_CR7","first-page":"411","volume":"10","author":"VK Sondak","year":"2011","unstructured":"Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P . Ipilimumab. Nat Rev 2011; 10: 411\u2013412.","journal-title":"Nat Rev"},{"key":"BFgt201317_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","volume":"58","author":"J Weber","year":"2009","unstructured":"Weber J . Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58: 823\u2013830.","journal-title":"Cancer Immunol Immunother"},{"key":"BFgt201317_CR9","first-page":"9","volume":"10","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Weber JS, Hamid O, Lebbe C, Maio M, Schadendorf D et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010; 10: 9.","journal-title":"Cancer Immun"},{"key":"BFgt201317_CR10","first-page":"1284","volume":"9","author":"PJ Bergman","year":"2003","unstructured":"Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 1284\u20131290.","journal-title":"Clin Cancer Res"},{"key":"BFgt201317_CR11","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1158\/1078-0432.CCR-07-0486","volume":"13","author":"CL Slingluff Jr.","year":"2007","unstructured":"Slingluff CL Jr., Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007; 13: 6386\u20136395.","journal-title":"Clin Cancer Res"},{"key":"BFgt201317_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.semcancer.2003.09.007","volume":"13","author":"T Talebi","year":"2003","unstructured":"Talebi T, Weber JS . Peptide vaccine trials for melanoma: preclinical background and clinical results. Sem Cancer Biol 2003; 13: 431\u2013438.","journal-title":"Sem Cancer Biol"},{"key":"BFgt201317_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/sj.cgt.7700676","volume":"11","author":"M Hisada","year":"2004","unstructured":"Hisada M, Yoshimoto T, Kamiya S, Magami Y, Miyaji H, Yoneto T et al. Synergistic antitumor effect by coexpression of chemokine CCL21\/SLC and costimulatory molecule LIGHT. Cancer Gene Ther 2004; 11: 280\u2013288.","journal-title":"Cancer Gene Ther"},{"key":"BFgt201317_CR14","first-page":"2062","volume":"61","author":"CJ Kirk","year":"2001","unstructured":"Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001; 61: 2062\u20132070.","journal-title":"Cancer Res"},{"key":"BFgt201317_CR15","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.4049\/jimmunol.164.9.4558","volume":"164","author":"S Sharma","year":"2000","unstructured":"Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000; 164: 4558\u20134563.","journal-title":"J Immunol"},{"key":"BFgt201317_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1749-6632.2009.04936.x","volume":"1174","author":"JJ Mule","year":"2009","unstructured":"Mule JJ . Dendritic cell-based vaccines for pancreatic cancer and melanoma. Ann N Y Acad Sci 2009; 1174: 33\u201340.","journal-title":"Ann N Y Acad Sci"},{"key":"BFgt201317_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/sj.cgt.7700671","volume":"11","author":"A Terando","year":"2004","unstructured":"Terando A, Roessler B, Mule JJ . Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther 2004; 11: 165\u2013173.","journal-title":"Cancer Gene Ther"},{"key":"BFgt201317_CR18","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1158\/1535-7163.MCT-06-0709","volume":"6","author":"L Novak","year":"2007","unstructured":"Novak L, Igoucheva O, Cho S, Alexeev V . Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther 2007; 6: 1755\u20131764.","journal-title":"Mol Cancer Ther"},{"key":"BFgt201317_CR19","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1158\/1078-0432.CCR-06-0979","volume":"12","author":"CR Ferrone","year":"2006","unstructured":"Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD et al. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res 2006; 12: 5511\u20135519.","journal-title":"Clin Cancer Res"},{"key":"BFgt201317_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1189\/jlb.0307133","volume":"82","author":"M Facco","year":"2007","unstructured":"Facco M, Baesso I, Miorin M, Bortoli M, Cabrelle A, Boscaro E et al. Expression and role of CCR6\/CCL20 chemokine axis in pulmonary sarcoidosis. J Leukocyte Biol 2007; 82: 946\u2013955.","journal-title":"J Leukocyte Biol"},{"key":"BFgt201317_CR21","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1084\/jem.20071397","volume":"204","author":"K Hirota","year":"2007","unstructured":"Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007; 204: 2803\u20132812.","journal-title":"J Exp Med"},{"key":"BFgt201317_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1600-0714.2006.00402.x","volume":"35","author":"M Ichimura","year":"2006","unstructured":"Ichimura M, Hiratsuka K, Ogura N, Utsunomiya T, Sakamaki H, Kondoh T et al. Expression profile of chemokines and chemokine receptors in epithelial cell layers of oral lichen planus. J Oral Pathol Med 2006; 35: 167\u2013174.","journal-title":"J Oral Pathol Med"},{"key":"BFgt201317_CR23","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.intimp.2009.03.019","volume":"9","author":"JH Guo","year":"2009","unstructured":"Guo JH, Fan MW, Sun JH, Jia R . Fusion of antigen to chemokine CCL20 or CXCL13 strategy to enhance DNA vaccine potency. Int Immunopharmacol 2009; 9: 925\u2013930.","journal-title":"Int Immunopharmacol"},{"key":"BFgt201317_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/CJI.0b013e31819d29d8","volume":"32","author":"NY Shih","year":"2009","unstructured":"Shih NY, Yang HY, Cheng HT, Hung YM, Yao YC, Zhu YH et al. Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine. J Immunother 2009; 32: 363\u2013369.","journal-title":"J Immunother"},{"key":"BFgt201317_CR25","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2353\/ajpath.2007.061275","volume":"171","author":"A Manzo","year":"2007","unstructured":"Manzo A, Bugatti S, Caporali R, Prevo R, Jackson DG, Uguccioni M et al. CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. Am J Pathol 2007; 171: 1549\u20131562.","journal-title":"Am J Pathol"},{"key":"BFgt201317_CR26","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/eji.200425830","volume":"35","author":"A Manzo","year":"2005","unstructured":"Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, Yanni G et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 2005; 35: 1347\u20131359.","journal-title":"Eur J Immunol"},{"key":"BFgt201317_CR27","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2353\/ajpath.2007.060817","volume":"170","author":"KG McDonald","year":"2007","unstructured":"McDonald KG, McDonough JS, Wang C, Kucharzik T, Williams IR, Newberry RD . CC chemokine receptor 6 expression by B lymphocytes is essential for the development of isolated lymphoid follicles. Am J Pathol 2007; 170: 1229\u20131240.","journal-title":"Am J Pathol"},{"key":"BFgt201317_CR28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/CJI.0b013e3181d75cef","volume":"33","author":"JY Park","year":"2010","unstructured":"Park JY, Jin DH, Lee CM, Jang MJ, Lee SY, Shin HS et al. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells. J Immunother 2010; 33: 510\u2013522.","journal-title":"J Immunother"},{"key":"BFgt201317_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/00002371-199909000-00007","volume":"22","author":"JS Weber","year":"1999","unstructured":"Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E . A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund\u2019s adjuvant in patients with resected high-risk melanoma. J Immunother 1999; 22: 431\u2013440.","journal-title":"J Immunother"},{"key":"BFgt201317_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1046\/j.1365-2567.2002.01396.x","volume":"106","author":"L BenMohamed","year":"2002","unstructured":"BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ . Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 2002; 106: 113\u2013121.","journal-title":"Immunology"},{"key":"BFgt201317_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0264-410X(97)00186-2","volume":"15","author":"MF del Guercio","year":"1997","unstructured":"del Guercio MF, Alexander J, Kubo RT, Arrhenius T, Maewal A, Appella E et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997; 15: 441\u2013448.","journal-title":"Vaccine"},{"key":"BFgt201317_CR32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/gt.2010.151","volume":"18","author":"A Wu","year":"2011","unstructured":"Wu A, Zeng Q, Kang TH, Peng S, Roosinovich E, Pai SI et al. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Therapy 2011; 18: 304\u2013312.","journal-title":"Gene Therapy"},{"key":"BFgt201317_CR33","first-page":"1197","volume":"22","author":"RC Chan","year":"2009","unstructured":"Chan RC, Gutierrez B, Ichim TE, Lin F . Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma. Oncol Rep 2009; 22: 1197\u20131203.","journal-title":"Oncol Rep"},{"key":"BFgt201317_CR34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1126\/science.1185837","volume":"328","author":"JD Shields","year":"2010","unstructured":"Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA . Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science (New York, NY) 2010; 328: 749\u2013752.","journal-title":"Science (New York, NY)"},{"key":"BFgt201317_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1755-148X.2009.00554.x","volume":"22","author":"A Richmond","year":"2009","unstructured":"Richmond A, Yang J, Su Y . The good and the bad of chemokines\/chemokine receptors in melanoma. Pigment Cell Melanoma Res 2009; 22: 175\u2013186.","journal-title":"Pigment Cell Melanoma Res"},{"key":"BFgt201317_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cellimm.2004.12.006","volume":"231","author":"K Flanagan","year":"2004","unstructured":"Flanagan K, Moroziewicz D, Kwak H, Horig H, Kaufman HL . The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol 2004; 231: 75\u201384.","journal-title":"Cell Immunol"},{"key":"BFgt201317_CR37","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1084\/jem.20092454","volume":"207","author":"ED Thompson","year":"2010","unstructured":"Thompson ED, Enriquez HL, Fu YX, Engelhard VH . Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 2010; 207: 1791\u20131804.","journal-title":"J Exp Med"},{"key":"BFgt201317_CR38","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.4049\/jimmunol.179.9.6009","volume":"179","author":"YX Chen","year":"2007","unstructured":"Chen YX, Man K, Ling GS, Chen Y, Sun BS, Cheng Q et al. A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J Immunol 2007; 179: 6009\u20136015.","journal-title":"J Immunol"},{"key":"BFgt201317_CR39","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/1521-4141(200204)32:4<994::AID-IMMU994>3.0.CO;2-6","volume":"32","author":"C Demangel","year":"2002","unstructured":"Demangel C, Bertolino P, Britton WJ . Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol 2002; 32: 994\u20131002.","journal-title":"Eur J Immunol"},{"key":"BFgt201317_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1177\/0961203307080226","volume":"16","author":"S Barath","year":"2007","unstructured":"Barath S, Aleksza M, Tarr T, Sipka S, Szegedi G, Kiss E . Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus. Lupus 2007; 16: 489\u2013496.","journal-title":"Lupus"},{"key":"BFgt201317_CR41","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/eji.200939513","volume":"40","author":"K Ohkusu-Tsukada","year":"2010","unstructured":"Ohkusu-Tsukada K, Toda M, Udono H, Kawakami Y, Takahashi K . Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy. Eur J Immunol 2010; 40: 1011\u20131021.","journal-title":"Eur J Immunol"},{"key":"BFgt201317_CR42","first-page":"4895","volume":"58","author":"MR Parkhurst","year":"1998","unstructured":"Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y . Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998; 58: 4895\u20134901.","journal-title":"Cancer Res"},{"key":"BFgt201317_CR43","doi-asserted-by":"publisher","first-page":"10577","DOI":"10.1073\/pnas.0700591104","volume":"104","author":"J Rangel-Moreno","year":"2007","unstructured":"Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Kusser K, Randall TD . Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc Natl Acad Sci USA 2007; 104: 10577\u201310582.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201317_CR44","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.4049\/jimmunol.161.12.6970","volume":"161","author":"SR Reynolds","year":"1998","unstructured":"Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D et al. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A\/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 1998; 161: 6970\u20136976.","journal-title":"J Immunol"},{"key":"BFgt201317_CR45","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/CMR.0b013e32832a1e18","volume":"19","author":"P Ghiorzo","year":"2009","unstructured":"Ghiorzo P, Pastorino L, Pizzichetta MA, Bono R, Queirolo P, Talamini R et al. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. Melanoma Res 2009; 19: 142\u2013145.","journal-title":"Melanoma Res"},{"key":"BFgt201317_CR46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/01.cmr.0000198452.03957.73","volume":"16","author":"A Wankowicz-Kalinska","year":"2006","unstructured":"Wankowicz-Kalinska A, Mailliard RB, Olson K, Graham F, Edington H, Kirkwood JM et al. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. Melanoma Res 2006; 16: 165\u2013174.","journal-title":"Melanoma Res"},{"key":"BFgt201317_CR47","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/23495","volume":"400","author":"JJ Campbell","year":"1999","unstructured":"Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999; 400: 776\u2013780.","journal-title":"Nature"},{"key":"BFgt201317_CR48","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran MA, Montalvo W, Yagita H, JP Allison . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107: 4275\u20134280.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt201317_CR49","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1006\/bbrc.1994.2036","volume":"202","author":"G Kroumpouzos","year":"1994","unstructured":"Kroumpouzos G, Urabe K, Kobayashi T, Sakai C, Hearing VJ . Functional analysis of the slaty gene product (TRP2) as dopachrome tautomerase and the effect of a point mutation on its catalytic function. Biochem Biophys Res Comm 1994; 202: 1060\u20131068.","journal-title":"Biochem Biophys Res Comm"},{"key":"BFgt201317_CR50","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4049\/jimmunol.165.2.613","volume":"165","author":"PJ Skinner","year":"2000","unstructured":"Skinner PJ, Daniels MA, Schmidt CS, Jameson SC, Haase AT . Cutting edge: in situ tetramer staining of antigen-specific T cells in tissues. J Immunol 2000; 165: 613\u2013617.","journal-title":"J Immunol"},{"key":"BFgt201317_CR51","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1016\/S0021-9258(18)94080-9","volume":"264","author":"M Jimenez","year":"1989","unstructured":"Jimenez M, Maloy WL, Hearing VJ . Specific identification of an authentic clone for mammalian tyrosinase. J Biol Chem 1989; 264: 3397\u20133403.","journal-title":"J Biol Chem"},{"key":"BFgt201317_CR52","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0021-9258(17)35295-X","volume":"266","author":"M Jimenez","year":"1991","unstructured":"Jimenez M, Tsukamoto K, Hearing VJ . Tyrosinases from two different loci are expressed by normal and by transformed melanocytes. J Biol Chem 1991; 266: 1147\u20131156.","journal-title":"J Biol Chem"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt201317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201317","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T20:45:27Z","timestamp":1688157927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,4]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFgt201317"],"URL":"https:\/\/doi.org\/10.1038\/gt.2013.17","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,4]]},"assertion":[{"value":"19 September 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}